An observational study in Coronary Disease and Young Adult, sponsored by Fu Wai Hospital, Beijing, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Fu Wai Hospital, Beijing, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 224 studies in Coronary Disease with a site in China — 68 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.
Among the 224 studies in Coronary Disease with a site in China, this one is the 15th largest by planned enrollment of the 82 observational ones that give a count, is one of 20 that started in 2025, is one of 82 observational ones, reaches primary completion later than 59 of the 77 other live ones, and was the 204th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →68 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Gan Lijun · Sites in China
Ages 18+
Xia Liang · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 10 · Phase 4 34
First in 1999; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 916 across 478 observational studies indexed under Coronary Disease.
Median enrollment 220 across the 142 interventional studies, 1,508 across the 82 observational. Of the 75 that completed or were terminated, 11 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 224 have an industry lead sponsor. The 10 most frequent:
Fu Wai Hospital, Beijing, China is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Fu Wai Hospital, Beijing, China has 2 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Coronary Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT06472908Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEfficacy and Safety of Colchicine After PCI | 2027-06-30 |
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07841275China Academy of Chinese Medical SciencesReal-World Effectiveness and Costs of Yiqi Fumai Lyophilized Injection in Coronary Heart Disease-Related Chronic Heart Failure | 2026-12 |
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 224 studies in Coronary Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is part of a nationwide research project in China that aims to better understand how coronary artery disease develops and progresses in young adults. The study will enroll approximately 10,000 participants aged 45 years or younger who undergo coronary CT scans at multiple hospitals across China.
Information collected at enrollment includes basic health information, cardiovascular risk factors, blood test results, medication use, lifestyle habits, and, for some participants, genetic data. Participants will undergo follow-up coronary CT scans after several years to evaluate changes in coronary artery plaque and disease progression.
By analyzing these clinical and imaging data, the study aims to identify factors associated with disease progression and to develop prediction models that may help estimate an individual's future risk of coronary plaque progression and cardiovascular events. The results of this study may contribute to improved risk assessment and early prevention strategies for coronary artery disease in young populations.
The study population includes adults aged 18 to 45 years with symptoms suggestive of coronary artery disease who undergo coronary computed tomography (CT) in participating centers across China. Participants are prospectively and consecutively enrolled into a nationwide observational registry after providing written informed consent and are followed longitudinally for disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression of Coronary Plaque on Computed Tomography
Progression of coronary atherosclerotic plaque assessed by comparing baseline and follow-up coronary computed tomography scans.
Time frame: From baseline to follow-up coronary CT, up to 3 years
Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.
Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 32 months is below that.
Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fu Wai Hospital, Beijing, China